Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer
Introduction: PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAE) that complicate management. Methods: We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012-2020 in a German academic center. Results: Ir...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 June 2021
|
| In: |
Frontiers in oncology
Year: 2021, Jahrgang: 11, Pages: 1-14 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2021.703893 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2021.703893 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2021.703893/full 
|
| Verfasserangaben: | Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1765670160 | ||
| 003 | DE-627 | ||
| 005 | 20251106123738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210805s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2021.703893 |2 doi | |
| 035 | |a (DE-627)1765670160 | ||
| 035 | |a (DE-599)KXP1765670160 | ||
| 035 | |a (OCoLC)1295679659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Daniello, Lea |d 1997- |e VerfasserIn |0 (DE-588)1238304303 |0 (DE-627)1765667739 |4 aut | |
| 245 | 1 | 0 | |a Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer |c Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos |
| 264 | 1 | |c 29 June 2021 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.08.2021 | ||
| 520 | |a Introduction: PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAE) that complicate management. Methods: We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012-2020 in a German academic center. Results: IrAE showed comparable frequencies in stage IV (198/894 or 22%) vs. III (14/45 or 31%, p=0.15), after anti-PD-(L)1 monotherapy vs. chemoimmunotherapy (139/483 vs. 58/213, p=0.75), and across treatment lines. In stage IV, irAE occurred after 3.1 months in median, affected multiple organs (median 2) in 27/894 patients, and were associated with PD-L1 positivity (25% vs. 14%, p=0.003), lower neutrophil-to-lymphocyte ratios (29% vs. 17%, p3 months), and average cumulative prednisone doses >700 mg for all organs, except for skin. Patients developing irAE had longer progression-free (PFS) and overall survival (OS) in multivariable 12/14-week landmark analyses including ECOG status, treatment line, treatment type, PD-L1 TPS, and NLR (median PFS 17 vs. 10 months, HR=0.68, p=0.009; median OS 37 vs. 15 months, HR=0.40, p<0.001), regardless of grade. OS was longest with skin (95% at 2 years) and shortest with pneumonitis, hepatitis, neurologic and cardiologic irAE (38%, 37%, 28%, and 0% at 2 years, p<0.001). Conclusions: Approximately one-fourth of immunotherapy-treated NSCLC patients develop irAE, most of which necessitate treatment suspension and steroids. Despite occurring more frequently with PD-L1 positive tumors, lower NLR, and better ECOG PS, irAE are independently associated with longer survival, especially when affecting the skin. Lethality is below 1%. | ||
| 650 | 4 | |a immune-checkpoint inhibitors | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Lethality | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a treatment interruption | |
| 700 | 1 | |a Elshiaty, Mariam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 700 | 1 | |a Kuon, Jonas |e VerfasserIn |0 (DE-588)1166909484 |0 (DE-627)1030803730 |0 (DE-576)510963129 |4 aut | |
| 700 | 1 | |a Kazdal, Daniel |d 1983- |e VerfasserIn |0 (DE-588)114929650X |0 (DE-627)1009614088 |0 (DE-576)496635867 |4 aut | |
| 700 | 1 | |a Schindler, Hannah |d 1998- |e VerfasserIn |0 (DE-588)1237666503 |0 (DE-627)1764596366 |4 aut | |
| 700 | 1 | |a Shah, Rajiv |d 1982- |e VerfasserIn |0 (DE-588)1074040481 |0 (DE-627)830206361 |0 (DE-576)435547690 |4 aut | |
| 700 | 1 | |a Volckmar, Anna-Lena |d 1984- |e VerfasserIn |0 (DE-588)173874916 |0 (DE-627)698776666 |0 (DE-576)134713478 |4 aut | |
| 700 | 1 | |a Lusky, Fabienne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diekmann, Leonore |d 1995- |e VerfasserIn |0 (DE-588)1292592443 |0 (DE-627)1848810164 |4 aut | |
| 700 | 1 | |a Liersch, Stephan |e VerfasserIn |0 (DE-588)1208635514 |0 (DE-627)1694944581 |4 aut | |
| 700 | 1 | |a Faehling, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 700 | 1 | |a Kriegsmann, Mark |d 1987- |e VerfasserIn |0 (DE-588)103740324X |0 (DE-627)755668782 |0 (DE-576)39141870X |4 aut | |
| 700 | 1 | |a Gente, Karolina |d 1986- |e VerfasserIn |0 (DE-588)1066617481 |0 (DE-627)817734120 |0 (DE-576)426070216 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 11(2021) vom: 29. Juni, Artikel-ID 703893, Seite 1-14 |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g day:29 |g month:06 |g elocationid:703893 |g pages:1-14 |g extent:14 |a Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2021.703893 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2021.703893/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210805 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 18 |y j | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |e 50000PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 17 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 16 | ||
| 998 | |g 1066617481 |a Gente, Karolina |m 1066617481:Gente, Karolina |d 910000 |d 910100 |e 910000PG1066617481 |e 910100PG1066617481 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 103740324X |a Kriegsmann, Mark |m 103740324X:Kriegsmann, Mark |d 910000 |d 912000 |d 50000 |e 910000PK103740324X |e 912000PK103740324X |e 50000PK103740324X |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 14 | ||
| 998 | |g 1056885432 |a Muley, Thomas |m 1056885432:Muley, Thomas |d 910000 |d 950000 |d 950900 |e 910000PM1056885432 |e 950000PM1056885432 |e 950900PM1056885432 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 13 | ||
| 998 | |g 1208635514 |a Liersch, Stephan |m 1208635514:Liersch, Stephan |d 910000 |d 950000 |d 950900 |e 910000PL1208635514 |e 950000PL1208635514 |e 950900PL1208635514 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 11 | ||
| 998 | |g 1292592443 |a Diekmann, Leonore |m 1292592443:Diekmann, Leonore |d 50000 |e 50000PD1292592443 |k 0/50000/ |p 10 | ||
| 998 | |g 173874916 |a Volckmar, Anna-Lena |m 173874916:Volckmar, Anna-Lena |d 910000 |d 912000 |e 910000PV173874916 |e 912000PV173874916 |k 0/910000/ |k 1/910000/912000/ |p 8 | ||
| 998 | |g 1074040481 |a Shah, Rajiv |m 1074040481:Shah, Rajiv |d 910000 |d 950000 |d 950900 |e 910000PS1074040481 |e 950000PS1074040481 |e 950900PS1074040481 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 998 | |g 1237666503 |a Schindler, Hannah |m 1237666503:Schindler, Hannah |d 50000 |e 50000PS1237666503 |k 0/50000/ |p 6 | ||
| 998 | |g 114929650X |a Kazdal, Daniel |m 114929650X:Kazdal, Daniel |d 910000 |d 912000 |e 910000PK114929650X |e 912000PK114929650X |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 998 | |g 1166909484 |a Kuon, Jonas |m 1166909484:Kuon, Jonas |d 910000 |d 910100 |d 50000 |e 910000PK1166909484 |e 910100PK1166909484 |e 50000PK1166909484 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 4 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |e 50000PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 3 | ||
| 998 | |g 1238304303 |a Daniello, Lea |m 1238304303:Daniello, Lea |d 50000 |e 50000PD1238304303 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1765670160 |e 3963263229 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"29 June 2021"}],"person":[{"given":"Lea","display":"Daniello, Lea","role":"aut","family":"Daniello"},{"given":"Mariam","family":"Elshiaty","role":"aut","display":"Elshiaty, Mariam"},{"given":"Farastuk","role":"aut","display":"Bozorgmehr, Farastuk","family":"Bozorgmehr"},{"given":"Jonas","display":"Kuon, Jonas","role":"aut","family":"Kuon"},{"given":"Daniel","family":"Kazdal","display":"Kazdal, Daniel","role":"aut"},{"role":"aut","display":"Schindler, Hannah","family":"Schindler","given":"Hannah"},{"given":"Rajiv","display":"Shah, Rajiv","role":"aut","family":"Shah"},{"given":"Anna-Lena","role":"aut","display":"Volckmar, Anna-Lena","family":"Volckmar"},{"given":"Fabienne","family":"Lusky","display":"Lusky, Fabienne","role":"aut"},{"display":"Diekmann, Leonore","role":"aut","family":"Diekmann","given":"Leonore"},{"display":"Liersch, Stephan","role":"aut","family":"Liersch","given":"Stephan"},{"role":"aut","display":"Faehling, Martin","family":"Faehling","given":"Martin"},{"given":"Thomas","role":"aut","display":"Muley, Thomas","family":"Muley"},{"role":"aut","display":"Kriegsmann, Mark","family":"Kriegsmann","given":"Mark"},{"given":"Karolina","display":"Gente, Karolina","role":"aut","family":"Gente"},{"family":"Stenzinger","role":"aut","display":"Stenzinger, Albrecht","given":"Albrecht"},{"family":"Thomas","display":"Thomas, Michael","role":"aut","given":"Michael"},{"given":"Petros","display":"Christopoulos, Petros","role":"aut","family":"Christopoulos"}],"id":{"eki":["1765670160"],"doi":["10.3389/fonc.2021.703893"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos"]},"title":[{"title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","title_sort":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer"}],"relHost":[{"title":[{"title_sort":"Frontiers in oncology","title":"Frontiers in oncology"}],"disp":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancerFrontiers in oncology","id":{"zdb":["2649216-7"],"issn":["2234-943X"],"eki":["684965518"]},"part":{"extent":"14","pages":"1-14","volume":"11","year":"2021","text":"11(2021) vom: 29. Juni, Artikel-ID 703893, Seite 1-14"},"origin":[{"publisherPlace":"Lausanne","dateIssuedKey":"2011","publisher":"Frontiers Media","dateIssuedDisp":"2011-"}],"pubHistory":["2011 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 07.11.13"],"recId":"684965518","physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"14 S."}],"recId":"1765670160","note":["Gesehen am 05.08.2021"],"language":["eng"]} | ||
| SRT | |a DANIELLOLETHERAPEUTI2920 | ||